Biogen Executive and Leadership Team

Christopher Viehbacher, the President & Chief Executive Officer at Biogen, directs the overarching corporate strategy for the development and commercialization of therapies targeting neurodegenerative diseases. Viehbacher architects the long-term vision for the biotechnology portfolio, ensuring alignment between research initiatives and market needs. By overseeing global operations, the President & Chief Executive Officer maintains focus on delivering innovative treatments for multiple sclerosis and spinal muscular atrophy. This leadership role involves constant engagement with the Board to drive sustainable growth and operational excellence across all international markets. Christopher Viehbacher manages the integration of gene-based therapies into the core business model to secure a competitive advantage in the pharmaceutical sector. Through disciplined resource allocation, the President & Chief Executive Officer optimizes the pipeline to address unmet medical needs, ultimately strengthening the market position of the organization within the complex landscape of modern neuroscience.

Robin Kramer, the Executive Vice President, Chief Financial Officer at Biogen, manages the global financial health and capital allocation strategies for the biotechnology enterprise. Kramer oversees financial planning, reporting, and investor relations to ensure the fiscal stability required for long-term investment in neuroscience research. By directing the financial architecture, the Executive Vice President, Chief Financial Officer supports the commercialization of therapies for rare neurological disorders. This leadership role involves collaborating with the executive team to evaluate the economic viability of new biologics and gene-based projects. Robin Kramer ensures that financial resources align with the strategic goals of the organization, fostering growth through disciplined investment. Through the management of global fiscal operations, the Executive Vice President, Chief Financial Officer provides the necessary foundation for the company to maintain its leadership in the pharmaceutical industry, ultimately securing the capital required to advance the next generation of neurological treatments.

Nicholas Colafemina, the Chief of Staff To the Chief Financial Officer. Director at Biogen, coordinates the administrative and strategic priorities of the finance department. Colafemina manages the flow of information between the Chief Financial Officer and other business units to ensure operational efficiency. By overseeing key financial projects, the Chief of Staff To the Chief Financial Officer. Director supports the execution of capital allocation strategies related to the development of neurodegenerative disease therapies. This role involves facilitating communication across the finance team to maintain alignment with corporate objectives. Nicholas Colafemina drives the implementation of internal processes that streamline financial reporting and resource management. Through the coordination of high-level initiatives, the Chief of Staff To the Chief Financial Officer. Director ensures that the financial leadership team remains focused on the core mission of delivering innovative biologics to patients, thereby supporting the overall financial health and strategic growth of the organization.

Andrew McKay, the Chief Financial Officer, Biogen (North America) at Biogen, manages the financial operations and fiscal strategy for the North American market. McKay oversees regional budgeting, financial forecasting, and resource allocation to support the commercialization of neurological therapies across the continent. By directing the financial performance of the North American business unit, the Chief Financial Officer, Biogen (North America) ensures that regional objectives align with the global corporate strategy. This role involves collaborating with commercial leaders to optimize the profitability of the product portfolio. Andrew McKay drives the implementation of financial controls that enhance operational efficiency and support the company's investment in neuroscience research. Through the management of regional fiscal activities, the Chief Financial Officer, Biogen (North America) provides the financial stability necessary for the company to maintain its competitive edge and continue delivering life-changing treatments to patients throughout the North American region.

Krystin Hein, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) at Biogen, coordinates strategic initiatives across medical affairs and neuropsychiatry departments. Hein manages operational workflows to ensure the efficient delivery of rare disease therapies within the United States market. By aligning cross-functional teams, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) facilitates the translation of clinical research into actionable patient care programs. This role involves monitoring performance metrics to optimize the commercialization of specialized neurological treatments. Krystin Hein drives the execution of medical strategy, ensuring that internal processes support the broader mission of addressing complex neurodegenerative conditions. Through rigorous oversight of operational activities, the Chief of Staff Strategy, Medical Affairs Rare Disease & Neuropsychiatry Operations Lead (US) enhances the effectiveness of medical outreach and patient support systems, contributing directly to the overall success of the therapeutic portfolio.

Tim McLoughlin, the Patient Services Chief of Staff at Biogen, directs the operational strategy for patient support programs related to the company's neurological therapy portfolio. McLoughlin manages the integration of patient services with commercial operations to ensure seamless access to treatments for multiple sclerosis and other rare disorders. By overseeing the delivery of support initiatives, the Patient Services Chief of Staff enhances the patient experience and improves therapy adherence. This role involves collaborating with medical and commercial teams to address the specific needs of the patient community. Tim McLoughlin drives the development of programs that simplify the journey for individuals requiring complex biologics. Through the management of patient-centric operations, the Patient Services Chief of Staff ensures that the company maintains its commitment to patient care, ultimately supporting the successful commercialization of therapies and strengthening the reputation of the organization within the global healthcare market.

Wendy Chen, the Chief Marketing Officer, Clinical Quality & Manager at Biogen, leads the commercial marketing strategy and clinical quality oversight for the company's therapeutic offerings. Chen architects the brand positioning for neurological treatments to ensure effective market penetration and patient awareness. By managing the intersection of marketing and clinical quality, the Chief Marketing Officer, Clinical Quality & Manager ensures that all promotional activities adhere to the highest standards of scientific accuracy and regulatory compliance. This role involves analyzing market trends to guide the commercialization of therapies for rare neurological disorders. Wendy Chen drives the development of marketing campaigns that highlight the clinical value of the company's biologics. Through the integration of quality management into marketing operations, the Chief Marketing Officer, Clinical Quality & Manager supports the sustainable growth of the product portfolio, ensuring that healthcare providers and patients understand the benefits of the company's innovative neuroscience solutions.

Kristin Melaugh, the Chief of Staff Commercial, SYFOVRE and EMPAVELI at Biogen, coordinates the commercial strategy and operational execution for specific therapeutic assets. Melaugh manages the cross-functional efforts required to bring these treatments to market effectively. By overseeing the commercialization roadmap, the Chief of Staff Commercial, SYFOVRE and EMPAVELI ensures that sales and marketing teams remain aligned with the strategic goals for these products. This role involves monitoring performance metrics and adjusting operational tactics to maximize the impact of these therapies in the treatment of rare disorders. Kristin Melaugh drives the coordination of resources to support the successful launch and ongoing commercial success of these key assets. Through the management of commercial operations, the Chief of Staff Commercial, SYFOVRE and EMPAVELI facilitates the delivery of essential treatments to patients, contributing to the overall growth and market presence of the company within the specialized pharmaceutical landscape.

Michael Parini, the Chief Legal Officer at Biogen, directs the legal, compliance, and regulatory affairs for the global biotechnology organization. Parini manages the legal framework surrounding the discovery, development, and commercialization of therapies for serious neurological diseases. By overseeing intellectual property protection and regulatory interactions, the Chief Legal Officer ensures that the company operates within the complex legal requirements of the pharmaceutical industry. This role involves providing strategic counsel to the executive team on risk management and corporate governance. Michael Parini drives the development of policies that uphold the highest ethical standards while supporting the company's mission to innovate in neuroscience. Through the management of legal operations, the Chief Legal Officer safeguards the company's assets and facilitates the successful navigation of regulatory landscapes, ultimately enabling the organization to focus on its core objective of delivering advanced biologics and gene-based therapies to patients worldwide.

Daniel Quirk, the Chief Medical Officer at Biogen, leads the medical strategy and clinical development programs for the company's portfolio of neurological and neurodegenerative therapies. Quirk oversees the scientific integrity of clinical trials and the medical evidence generation required for the commercialization of new treatments. By directing the medical affairs team, the Chief Medical Officer ensures that the company's research initiatives address the most critical needs in neuroscience. This role involves collaborating with the research and development department to advance the pipeline of biologics and gene-based therapies. Daniel Quirk drives the communication of clinical data to the medical community, fostering understanding of the company's therapeutic innovations. Through the management of medical operations, the Chief Medical Officer ensures that all clinical activities support the company's mission to improve patient outcomes, ultimately strengthening the scientific foundation of the organization's market-leading position in the pharmaceutical sector.